OptiNose (NASDAQ:OPTN) Trading Up 3.1%

OptiNose Inc (NASDAQ:OPTN) was up 3.1% during trading on Monday . The stock traded as high as $6.72 and last traded at $6.55, approximately 14,407 shares were traded during trading. A decline of 94% from the average daily volume of 237,919 shares. The stock had previously closed at $6.35.

Several research analysts have commented on OPTN shares. Piper Jaffray Companies set a $29.00 price objective on shares of OptiNose and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. Royal Bank of Canada set a $20.00 price objective on shares of OptiNose and gave the stock a “buy” rating in a research note on Monday, August 12th. BMO Capital Markets decreased their target price on OptiNose from $26.00 to $24.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Zacks Investment Research downgraded OptiNose from a “buy” rating to a “hold” rating in a research report on Thursday, July 11th. Finally, ValuEngine upgraded OptiNose from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. OptiNose currently has an average rating of “Buy” and an average target price of $21.50.

The firm has a market capitalization of $281.38 million, a P/E ratio of -2.42 and a beta of 0.90. The firm has a 50-day moving average price of $6.21 and a two-hundred day moving average price of $7.95. The company has a debt-to-equity ratio of 1.06, a current ratio of 6.60 and a quick ratio of 6.74.

OptiNose (NASDAQ:OPTN) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.09. The firm had revenue of $6.68 million during the quarter, compared to the consensus estimate of $7.74 million. OptiNose had a negative return on equity of 102.10% and a negative net margin of 670.20%. Sell-side analysts predict that OptiNose Inc will post -2.74 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its holdings in shares of OptiNose by 1,569.2% in the first quarter. BNP Paribas Arbitrage SA now owns 4,006 shares of the company’s stock valued at $41,000 after acquiring an additional 3,766 shares in the last quarter. Stifel Financial Corp purchased a new position in OptiNose in the fourth quarter valued at about $63,000. UBS Asset Management Americas Inc. purchased a new position in OptiNose in the second quarter valued at about $72,000. Susquehanna International Group LLP purchased a new position in OptiNose in the second quarter valued at about $77,000. Finally, Paradigm Capital Management Inc. NY purchased a new position in OptiNose in the second quarter valued at about $78,000. Hedge funds and other institutional investors own 66.81% of the company’s stock.

OptiNose Company Profile (NASDAQ:OPTN)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Read More: What is meant by holder of record?

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.